var data={"title":"Technetium Tc-99m pentetate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m pentetate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/383893?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-pentetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m pentetate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734585\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Drax Image DTPA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106639\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106656\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Measure dose with appropriate radioactivity calibration system immediately prior to administration. Do not administer more than 1 dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain imaging:</b> IV: 10 to 20 mCi (370 to 740 MBq). Immediate dynamic imaging; obtain at least 1 blood-pool image in same position as flow; delayed images may be obtained 1 hour later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GFR estimation (with renal visualization):</b> IV: 3 to 5 mCi (111 to 185 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GFR estimation (no renal imaging):</b> IV: 0.2 to 0.5 mCi (7.4 to 18.5 MBq). Blood sampling only is performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal perfusion assessment (with renal visualization):</b> IV: 10 to 20 mCi (370 to 740 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CSF leak detection (off-label use):</b> Intrathecal: Subarachnoid injection: 1 to 3 mCi (37 to 11 MBq) (Kowalsky 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystography, retrograde (off-label use): </b>Intracatheter (urethral): 0.5 to 1 mCi (18.5 to 37 MBq) (ACR 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystography, anterograde (off-label use):</b> IV: 10 to 15 mCi (ACR 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Evaluation of renovascular hypertension (off-label use):</b> IV: 1 to 10 mCi (185 to 370 MBq) (Taylor 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung ventilation: </b>Inhalation (via nebulizer): 25 to 50 mCi (925 to 1850 MBq); to achieve a lung dose of ~0.5 to 1 mCi (18.5 to 37 MBq). For imaging performed prior to perfusion imaging, the target dose is achieved after 3 to 5 minutes of inhalation or at an imaging count of 50,000 to 100,000/minute; for imaging performed after perfusion imaging, target count rate should be ~3 times that of perfusion count rate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106655\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Measure dose with appropriate radioactivity calibration system immediately prior to administration. Do not administer more than 1 dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain imaging (off-label use):</b> IV: 0.2 mCi/kg (7.4 MBq/kg); minimum: 10 mCi (370 MBq); maximum: 20 mCi (740 MBq) (Donohoe 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystography, anterograde (off-label use):</b> IV: 0.1 to 0.2 mCi/kg (3.7 to 7.4 MBq/kg); minimum: 1 mCi (37 MBq); maximum: 10 mCi (370 MBq) (ACR 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystography, retrograde (off-label use):</b> Intracatheter (urethral): 0.5 to 1 mCi (18.5 to 37 MBq); may consider 0.25 to 0.5 mCi (9.25 to 18.5 MBq) in infants and toddlers (ACR 2010); do not exceed 1 mCi (37MBq) per bladder-filling cycle (Gelfand 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diuretic renography (off-label use):</b> IV: 0.1 mCi/kg (3.7 MBq/kg); minimum: 1 mCi (37 MBq) (Shulkin 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Evaluation of renovascular hypertension (off-label use):</b> IV: 0.1 mCi/kg (3.7 MBq/kg) (Taylor 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GFR estimation (no renal imaging):</b> IV: 0.2 to 0.5 mCi (7.4 to 18.5 MBq). Blood sampling only is performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung ventilation:</b> Inhalation (via nebulizer): 25 mCi (925 MBq); to achieve a lung dose of ~0.5 mCi (18.5 MBq). For imaging performed prior to perfusion imaging, the target dose is achieved at an imaging count of ~10,000 to 50,000/minute; for imaging performed after perfusion imaging, target count rate should be ~3 times that of perfusion count rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal perfusion assessment (with renal visualization):</b> IV: 0.1 to 0.2 mCi<b>/kg</b> (3.7 to 7.4 MBq<b>/kg</b>); minimum dose: 1 mCi (37 MBq); maximum dose: 5 mCi (185 MBq). Immediate dynamic imaging; static imaging 1 to 30 minutes after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106684\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106657\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106658\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106666\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Drax Image DTPA: Lyophilized pentetic acid mixture to be combined with sodium pertechnetate Tc99m injection solution (5s, 30s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106638\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106659\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: A disposable nebulizer is required. Rinse mouth and expectorate after use to minimize mouth and esophagus radiation exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Not for direct IV injection; only reconstituted technetium Tc 99m pentetate may be administered IV. See manufacturer's prescribing information for complete administration procedure. Ensure adequate hydration before and after administration; void frequently for 4 to 6 hours post administration to minimize bladder radiation exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734587\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Imaging agent: </b>Radiopharmaceutical imaging agent used for brain imaging; renal visualization for renal perfusion assessment and glomerular filtration rate (GFR) estimation; lung ventilation imaging and evaluation of pulmonary embolism when used in combination with perfusion imaging</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106640\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Brain imaging (pediatric); Cystography; Diuretic renography (pediatric); Renovascular hypertension (evaluation); CSF leak detection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734583\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106649\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, chills, cyanosis, dizziness, erythema, headache, hypersensitivity reaction, hypertension, hypotension, nausea, pruritus, skin rash, syncope, tachycardia, throat irritation, urticaria, vomiting, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106679\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to technetium Tc 99m pentetate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106647\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May result in acute bronchospasm especially in patients with heightened bronchoreactivity (eg, asthma or other lung or allergic disorders); monitor all patients for bronchoconstriction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported; appropriate equipment and personnel to manage hypersensitivity should be available during use. Monitor for hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation accumulation: Tc 99m administration contributes to the patient&rsquo;s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Use the lowest dose necessary for imaging. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Risk is greater with pediatric patients due to greater radiosensitivity and longer life expectancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients receiving kidney imaging should be adequately hydrated prior to dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lung ventilation study: In patients with obstructive pulmonary disease there may be deposition of particles in the proximal airways which may influence the image quality and interfere with diagnostic interpretation; careful nebulizer use is essential to assure optimal particle delivery and ensure diagnostic quality. Consider additional diagnostic options if particle deposition occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risk for misinterpretation: Image interpretation errors may occur with Tc 99m pentetate. Deposition of particles in the proximal airways may influence image quality and diagnostic interpretation; optimal particle delivery is essential therefore careful use of the nebulizer is important to ensure diagnostic quality. Consider additional diagnostic options if interference occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407238\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407235\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101538&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106644\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999). The diagnostic use of technetium Tc 99m pentetate in pregnant patients has been reported (Goldstein 1988; Griffith 1992). Increased fluid intake and frequent voiding can reduce potential fetal exposure (Adelstein 1999; Goldstein 1988; ICRP 2000). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein 1999; ICRP 2000; Parker 2004). Pregnancy status should be determined in women of childbearing potential (Parker 2004). The manufacturer recommends that elective procedures done in women of reproductive potential be conducted within the first few (~10) days following onset of menses. Guidelines are available as to when lung scintigraphy for the diagnosis of pulmonary embolism should be done in pregnant women (Leung 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106646\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if technetium Tc 99m is present in breast milk. According to the manufacturer, the decision to discontinue breastfeeding during therapy should take into account the benefits of breastfeeding to the infant and the diagnostic needs of the mother. Most sources recommended stopping breast-feeding for &ge;4 hours (Ahlgren 1985; ICRP 2000; Mountford 1989; Stabin 2000); however, because excretion of technetium Tc 99 pentetate into breast milk can be widely variable, other sources recommended stopping breastfeeding for &le;12 hours (Harding 1995) or longer while monitoring milk concentrations (Rubow 1994).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, following the administration of radiopharmaceuticals, women with a well-established milk supply should pump at normal feeding times and discard the milk until breast-feeding may be resumed (Harding 1995; Mountford 1989). Excretion of Technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breast-feeding cannot be made (Mountford 1989; Rubow 1994). Elective diagnostic procedures should be delayed until breast-feeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51090079\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs/symptoms of acute bronchospasm and hypersensitivity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51090073\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106681\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: Vss: 17 L; distributed throughout extracellular fluid space</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Inhalation: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: IV: ~4% to 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: 2.1 hours; Decay half-life: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Inhalation: &lt;2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: IV: Urine (~100%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27774699\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>DTPA (CZ);</li>\n      <li>Pentastan (AU);</li>\n      <li>Technescan DTPA (CH, FR, HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlgren L, Ivarsson S, Johansson L, et al, &quot;Excretion of Radionuclides in Human Breast Milk After the Administration of Radiopharmaceuticals,&quot;<i> J Nucl Med</i>, 1985, 26(9):1085-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/4032049/pubmed\" target=\"_blank\" id=\"4032049\">4032049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR) and Society for Pediatric Radiology (SPR), &quot;ACR-SPR Practice Guideline for the Performance of Adult and Pediatric Renal Scintigraphy,&quot; 2014. Available at http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/Renal_Scintigraphy.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR), Society for Pediatric Radiology (SPR), and Society of Nuclear Medicine (SNM), &quot;ACR-SPR-SNM Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography,&quot; 2010. Available at http://snmmi.files.cms-plus.com/docs/Radionuclide_Cystography_1382732076756_9.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donohoe KJ, Frey KA, Gerbaudo VH, et al, &quot;Procedure Guideline for Brain Death Scintigraphy,&quot; J Nucl Med, 2003, 44(5):846-51. Available at http://interactive.snm.org/docs/pg_ch20_0403.pdf12732688</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Draximage DTPA (technetium Tc 99m pentetate) [prescribing information]. Kirkland, Quebec, Canada: Jubilant DraxImage Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelfand MJ, Parisi MT, Treves ST, et al, &quot;Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines,&quot; J Nucl Med, 2011, 52(2):318-22. Available at http://jnm.snmjournals.org/content/52/2/318.full.pdf+html21233182</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein HA, Ziessman HA, Fahey FH, et al, &quot;Renal Scans in Pregnant Transplant Patients,&quot; <i>J Nucl Med</i>, 1988, 29(8):1364-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/3042923/pubmed\" target=\"_blank\" id=\"3042923\">3042923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith D, Alexander M, Gelman R, et al, &quot;Normal Uptake in a Gravid Uterus on Tc-99m DTPA Imaging,&quot; <i>Clin Nucl Med</i>, 1992, 17(9):736-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/1395349/pubmed\" target=\"_blank\" id=\"1395349\">1395349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaya M, Ustun F, Gultekin A, et al, &quot;Secretion of Radioactivity in Breast Milk After Tc-99m DTPA Aerosol and Tc-99m MAA Lung Imaging,&quot; <i>Clin Nucl Med</i>, 2001, 26(7):657-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/11416765/pubmed\" target=\"_blank\" id=\"11416765\">11416765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kowalsky RJ and Falen SW, <i>Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine</i>, 2nd ed, Washington, DC: American Pharmacists Association, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leung AN, Bull TM, Jaeschke R, et al, &quot;An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism in Pregnancy,&quot; <i>Am J Respir Crit Care Med</i>, 2011, 184(10):1200-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/22086989/pubmed\" target=\"_blank\" id=\"22086989\">22086989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulkin BL, Mandell GA, Cooper JA, et al, &quot;Procedure Guideline for Diuretic Renography in Children 3.0,&quot; J Nucl Med Technol, 2008, 36(3):162-8. Available at http://interactive.snm.org/docs/162.pdf18765635</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Society of Nuclear Medicine, &ldquo;SNM Practice Guideline for Lung Scintigraphy V4.0,&rdquo; 2011. Available at http://interactive.snm.org/docs/Lung_Scintigraphy_V4_Final.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stabin MG and Breitz HB, &quot;Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry,&quot; <i>J Nucl Med</i>, 2000, 41(5):863-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-pentetate-drug-information/abstract-text/10809203/pubmed\" target=\"_blank\" id=\"10809203\">10809203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor AT Jr, Blaufox MD, Dubovsky EV, et al, &quot;Society of Nuclear Medicine Procedure Guideline for Diagnosis of Renovascular Hypertension,&quot; 2003. Available at: http://interactive.snm.org/docs/pg_ch16_0403.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101538 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7734585\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28106639\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28106656\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28106655\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28106684\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28106657\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28106658\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28106666\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28106638\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28106659\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7734587\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28106640\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7734583\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28106649\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28106679\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28106647\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28407238\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28407235\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28106644\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28106646\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F51090079\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F51090073\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28106681\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27774699\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101538|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-pentetate-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m pentetate: Patient drug information</a></li></ul></div></div>","javascript":null}